Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses
Status:
Completed
Trial end date:
2014-02-21
Target enrollment:
Participant gender:
Summary
GSK2140944 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of
antibiotics. GSK2140944 has demonstrated in vitro and in vivo activity against Gram positive
pathogens including methicillin resistant Staphylococcus aureus (MRSA) and Gram-negative
pathogens associated with respiratory tract, skin and soft tissue infections including
isolates resistant to existing classes of antimicrobials.